Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2031-09-30
Target enrollment:
Participant gender:
Summary
The OASIS II trial is a multicentre, open label, randomized phase II trial. We will compare
the efficacy of Ibrutinib/anti-CD20 Ab versus Ibrutinib/anti-CD20 Ab/Venetoclax given as
fixed duration combinations in newly diagnosed Mantle Cell Lymphoma (MCL) patients (≥ 18
years and < 80 years of age).
Treatment duration of Ibrutinib and Venetoclax will be a maximum of two years. Patients will
be treated with CD20 Ab for 3.5 years.
The primary aim is to assess MRD status at 6 months in both arms.